• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Cardeon

0.05 SEK

0.00 %

Less than 1K followers

CARDEO

NGM Growth Market

Investment

Financials

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
0.00 %
-3.85 %
+35.14 %
+11.11 %
+6.38 %
-41.18 %
-82.76 %
-94.97 %
-98.08 %

Cardeon is a Swedish investment company that invests in Nordic companies and startups within medical technology and life science. The company's business concept is to assist in the development of an idea from a research result to a commercial product through investments. The target companies are to be assessed as having the potential to change the global market. Cardeon invests in both listed and unlisted companies and was founded in 2006.

Read more
Market cap
42.02M SEK
Turnover
3.84K SEK
Revenue
5.54M
EBIT %
-144.4 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
24/6
2026

General meeting '26

28/8
2026

Interim report Q2'26

19/11
2026

Interim report Q3'26

Regulatory press release5/22/2026, 8:20 AM

KALLELSE TILL ÅRSSTÄMMA I CARDEON AB (PUBL)

Cardeon
Regulatory press release5/21/2026, 3:00 PM

Cardeon AB (publ) publicerar delårsrapport 1 2026

Cardeon
Regulatory press release5/20/2026, 4:00 PM

Cardeon AB (publ) publicerar årsredovisning för 2025

Cardeon

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release2/25/2026, 7:30 AM

Cardeon AB publicerar bokslutskommuniké 2025

Cardeon
Press release1/15/2026, 1:15 PM

Kalqyl: Cardeon: NGM Company Insights

Cardeon
Regulatory press release11/20/2025, 7:30 AM

Cardeon AB (publ) publicerar delårsrapport 3 2025

Cardeon
Regulatory press release11/12/2025, 7:00 AM

Cardeon - Går in i värdehöjande period - Mangold Insight

Cardeon
Press release11/10/2025, 2:25 PM

Cardeons portföljbolag SpectraCure meddelade i förra veckan goda resultat avseende PSA-värden i klinisk studie för återfall av prostatacancer

Cardeon
Press release10/24/2025, 8:45 AM

Cardeons portföljbolag Deep Light Vision får EU-anslag för utveckling av metod för medicinsk bilddiagnostik

Cardeon
Press release10/23/2025, 9:15 AM

Cardeons portföljbolag TEQCool finansierat för fortsatt genomförande – bolaget fortsätter enligt plan

Cardeon
Press release10/17/2025, 8:20 AM

Cardeons portföljbolag AcroPharma ingår forskningsavtal med Lunds Universitet

Cardeon
Press release10/15/2025, 8:40 AM

Lovande framsteg för Cardeons portföljbolag AcroPharma – ny behandling mot typ 2-diabetes går mot fas 2 studie

Cardeon
Press release9/22/2025, 8:15 AM

Cardeons portföljbolag SpectraCure visar positiva 12-månadersresultat i klinisk studie för återfall av prostatacancer vid MSKCC

Cardeon
Press release9/12/2025, 8:05 AM

Cardeons portföljbolag SpectraCure redovisar positiva resultat i den kliniska studien för primär lokaliserad prostatacancer

Cardeon
Press release9/11/2025, 11:30 AM

Cardeons portföljbolag SpectraCure får expertgruppens bekräftelse på säkerhet och lovande kliniska resultat i pågående studie för återfall i prostatacancer

Cardeon
Press release9/10/2025, 12:10 PM

Cardeons portföljbolag AcroPharma har lämnat Internationell patentansökan för Peptidagonister av GPR56 receptorn

Cardeon
Press release8/29/2025, 7:00 AM

Cardeon välkomnar AcroPharmas investerarbrev – tydliga framsteg inom utveckling, IP och klinisk plan

Cardeon
Regulatory press release8/28/2025, 1:00 PM

Cardeon AB (publ) publicerar delårsrapport 2 2025

Cardeon
Press release7/21/2025, 1:30 PM

Cardeons portföljbolag SpectraCure har genomfört första patientbehandlingen i klinisk studie för primär lokaliserad prostatacancer

Cardeon
Press release6/26/2025, 1:00 PM

VD-kommentar inför sommaren

Cardeon